The estimated Net Worth of James B. Mc Nally is at least $6.32 million dollars as of 25 November 2019. James Nally owns over 2,288 units of GenMark Diagnostics Inc stock worth over $6,081,711 and over the last 8 years James sold GNMK stock worth over $234,398.
Sign up
James Nally GNMK stock SEC Form 4 insiders trading
James has made over 20 trades of the GenMark Diagnostics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently James sold 2,288 units of GNMK stock worth $12,424 on 25 November 2019.
The largest trade James's ever made was selling 12,297 units of GenMark Diagnostics Inc stock on 25 February 2019 worth over $83,497. On average, James trades about 1,872 units every 29 days since 2016. As of 25 November 2019 James still owns at least 252,983 units of GenMark Diagnostics Inc stock.
You can see the complete history of James Nally stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at GenMark Diagnostics Inc
Over the last 14 years, insiders at GenMark Diagnostics Inc have traded over $27,572,889 worth of GenMark Diagnostics Inc stock and bought 454,838 units worth $2,182,328 . The most active insiders traders include Hany Massarany, Jon Faiz Kayyem et Kevin C Oboyle. On average, GenMark Diagnostics Inc executives and independent directors trade stock every 5 days with the average trade being worth of $141,403. The most recent stock trade was executed by Michael Gleeson on 14 April 2021, trading 27,667 units of GNMK stock currently worth $326,471.
What does GenMark Diagnostics Inc's logo look like?
Complete history of James Nally stock trades at GenMark Diagnostics Inc
GenMark Diagnostics Inc executives and stock owners
GenMark Diagnostics Inc executives and other stock owners filed with the SEC include:
-
Scott Mendel,
President, Chief Executive Officer, Director -
Johnny Ek,
Chief Financial Officer -
Michael Gleeson,
Senior Vice President, Corporate Accounts -
Eric Stier,
Senior Vice President, General Counsel, Secretary -
James Fox,
Non-Executive Independent Director -
Kevin O'Boyle,
Independent Chairman of the Board -
Lisa Giles,
Independent Director -
Daryl Faulkner,
Independent Director -
Michael Kagnoff,
Independent Director -
Tyler Jensen,
Senior Vice President - Engineering and Product Technical Support -
Jon Faiz Kayyem,
President & CEO -
Jennifer Anne Williams,
SVP Global Operations -
Wade R. Stevenson,
SVP, North America Sales -
Brian Andrew Mitchell,
SVP, Operations -
Christine Shaw,
VP, Assay Development -
John Frederick Ek,
Chief Financial Officer -
Richard B Slansky,
Chief Financial Officer -
Stephen T Worland,
Director -
Jeffrey Alan Hawkins,
SVP, Marketing & Bus Dev -
Ingo Chakravarty,
SVP, International -
Christopher M Gleeson,
Director -
James B. Mc Nally,
SVP, Marketing and Bus. Dev. -
Jorge Garces,
SVP, Research & Development -
Paul Ross,
CFO & Secretary -
Pankaj Singhal,
Sr. VP, Product Dev & Mftg -
Matthew Robert Cohen,
SVP, Gen Counsel & Secretary -
John Bellano,
SR. VP, Commercial Operations -
Steven J Kemper,
CFO, Treasurer & Secretary -
Bradley Calvin,
Senior VP, Global Marketing -
Scott Alexander O'brien,
SVP, Global Mktg & Int'l Sales -
Hany Massarany,
President and CEO -
Sarah Hollis Winkler,
VP, Human Resources -
Alan Baer Maderazo,
VP, Qual, Reg, & Clin Affairs -
Michael John Harkins,
SVP, Sales -
Abdul Chohan,
SVP Operations